ATRA · Atara Biotherapeutics, Inc. · Share Buybacks
$9.38
-0.51 (-5.16%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$94.15M
Shares
10.04M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2023-11 | — | $100,000,000 | $84,200,000 as of 2026-03-31 | — | 10-Q , filed 2026-05-12 |
Key facts
CIK
1604464
CUSIP
046513206
13F (30d)
14 filings
14 filers
Visit website
Investor relations